

### *ESG Investor Event: Sanofi presents its integrated CSR strategy*

- Sanofi to highlight its integrated CSR strategy enabling value creation and cultural transformation for the company as well as executing on its commitment to society
- Showcases key programs across its four CSR pillars designed to expand access to medicines, advance R&D for unmet needs, reach carbon neutrality and net-zero, and drive diversity, equity and inclusion in and beyond the workplace
- The hybrid ESG Investor Event will take place from 2 p.m. to 5.30 p.m. CET / 8 a.m. to 11.30 a.m. EST (webcast, in-person meeting at Sanofi Paris Headquarters)

**PARIS – July 5, 2022** – Today, Sanofi hosts a hybrid ESG Investor Event to present its key CSR programs and discuss the CSR strategy. The CSR strategy is embedded within its broader Play to Win strategy to help create value and propel the cultural transformation of the company. The integrated approach also aims to have a meaningful positive impact on society.

#### ***Paul Hudson***

Chief Executive Officer, Sanofi

*“At Sanofi, we believe we have a responsibility to make a difference to the health of our communities and for the care of the planet. We want to elevate our ambition for our Corporate Social Responsibility strategy and ensure it is fully embedded into our mission to chase the miracles of science and to improve people’s lives, with the vision for a better future. At Sanofi, we strive to do more.”*

Sanofi has been steadily advancing on the implementation of its CSR strategy since 2020 along four key pillars:

To further improve **Affordable access** to medicines, Sanofi has made significant progress since the launch of its Global Health Unit (GHU) a year ago. The event highlights achievements of the GHU since its creation including the recently announced launch of an impact investment fund that will support start-up companies and other innovators that can deliver scalable solutions for sustainable healthcare in underserved regions. In parallel, Sanofi GHU is also launching Impact®, the new GHU dedicated brand for non-profit distribution and that will enable the secure distribution of 30 Sanofi medicines in 40 lower-income countries.

With its focus on **R&D for unmet needs**, the elimination of sleeping sickness has been a long-standing mission for Sanofi, where the company continues to do more to change the treatment paradigm for the most vulnerable communities.

As part of Sanofi’s efforts for **Planet care**, the company announced its ambition to be carbon neutral by 2030 and net zero by 2050 last year, which marks an acceleration of 20 years versus its previous commitments. This year, Sanofi will outline its roadmap to reach carbon neutrality by 2030 and illustrate the positive impact of carbon offsetting programs on communities as well as the environment, contributing to its 2050 net zero commitment.

To ensure its **Diversity, Equity & Inclusion (DE&I)** strategy is rightly executed, monitor progress on the company’s 2025 targets and learn from external thought-leaders, Sanofi announced the creation of its first DE&I board in April 2022. Dr Rohini Anand, DE&I board member and renowned thought-leader, will be joining the event for a conversation on Sanofi DE&I ambitions **in and beyond the workplace**.

### ***Sandrine Bouttier Stref***

Head of Corporate Social Responsibility, Sanofi

*We have effectively initiated a process of transformation and support for CSR within the company. We believe in CSR as a cultural transformation and value creation enabler. We are on the move and we are making great strides.*

Finally, a panel discussion with Paul Hudson, Sanofi CEO, Lise Kingo, Sanofi Board Director, Sandrine Bouttier Stref, Head of CSR, moderated by Thomas Scheiwiller, co-founder of the Biopharma Sustainability Roundtable will wrap up the event focusing on how governance is instrumental in embedding and integrating Sanofi's CSR commitments into all its activities.

ESG Investor Event details

For background slides and webcast, please refer to the following link:

<https://www.sanofi.com/en/investors/financial-results-and-events/investor-presentations/ESG-Investor-Event-2022>

---

### ***About Sanofi***

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on Euronext: SAN and NASDAQ: SNY

### ***Investor Relations***

**Eva Schaefer-Jansen** | + 33 7 86 80 56 39 | [eva.schaefer-jansen@sanofi.com](mailto:eva.schaefer-jansen@sanofi.com)

**Arnaud Delépine** | + 33 6 73 69 36 93 | [arnaud.delepine@sanofi.com](mailto:arnaud.delepine@sanofi.com)

**Corentine Driancourt** | + 33 6 40 56 92 21 | [corentine.driancourt@sanofi.com](mailto:corentine.driancourt@sanofi.com)

**Felix Lauscher** | + 1 908 612 7239 | [felix.lauscher@sanofi.com](mailto:felix.lauscher@sanofi.com)

**Priya Nanduri** | +1 617 764 6418 | [priya.nanduri@sanofi.com](mailto:priya.nanduri@sanofi.com)

**Nathalie Pham** | + 33 7 85 93 30 17 | [nathalie.pham@sanofi.com](mailto:nathalie.pham@sanofi.com)

---